Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the 91st Annual Meeting of the American Thyroid Association (ATA 2022) in Montreal, October 19-23.
TEPEZZA is the first and only medicine approved by the FDA for the treatment of TED. It is only approved in the U.S.
'Our understanding of Thyroid Eye Disease is ever-evolving, and we are committed to ongoing research that reflects the experiences of those living with this debilitating disease,' said Jeffrey W. Sherman, M.D., FACP, executive vice president, chief medical officer, Horizon. 'We look forward to bringing these important data to the forefront to help physicians better understand the condition for their patients.'
https://www.marketscreener.com/quote/stock/HORIZON-THERAPEUTICS-PUBL-18100076/news/Horizon-Therapeutics-plc-to-Present-New-Data-on-TEPEZZA-and-Thyroid-Eye-Disease-at-the-American-Thyr-42009896/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.